Articles

Diverse proteins aggregate in mild cognitive impairment and Alzheimer’s disease brain

All cells accumulate insoluble protein aggregates throughout their lifespan. While many studies have characterized the canonical disease-associated protein aggregates, such as those associated with amyloid pla...

Authors: Devin Kepchia, Ling Huang, Richard Dargusch, Robert A. Rissman, Maxim N. Shokhirev, Wolfgang Fischer and David Schubert

The dynamics of biomarkers across the clinical spectrum of Alzheimer’s disease

Quantifying changes in the levels of biological and cognitive markers prior to the clinical presentation of Alzheimer’s disease (AD) will provide a template for understanding the underlying aetiology of the cl...

Authors: Christoforos Hadjichrysanthou, Stephanie Evans, Sumali Bajaj, Loizos C. Siakallis, Kevin McRae-McKee, Frank de Wolf and Roy M. Anderson

Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases

The retina and the brain share anatomic, embryologic, and physiologic characteristics. Therefore, retinal imaging in patients with brain disorders has been of significant interest. Using optical coherence tomo...

Authors: Ju-Yeun Lee, Jun Pyo Kim, Hyemin Jang, Jaeho Kim, Sung Hoon Kang, Ji Sun Kim, Jongmin Lee, Young Hee Jung, Duk L. Na, Sang Won Seo, Sei Yeul Oh and Hee Jin Kim

Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology

Heme and iron homeostasis is perturbed in Alzheimer’s disease (AD); therefore, the aim of the study was to examine the levels and association of heme with iron-binding plasma proteins in cognitively normal (CN...

Authors: Azhaar Ashraf, Nicholas J. Ashton, Pratishtha Chatterjee, Kathryn Goozee, Kaikai Shen, Jurgen Fripp, David Ames, Christopher Rowe, Colin L. Masters, Victor Villemagne, Abdul Hye, Ralph N. Martins and Po-Wah So

Correction to: Relevance of biomarkers across different neurodegenerative diseases

An amendment to this paper has been published and can be accessed via the original article.

Authors: Alexander J. Ehrenberg, Ayesha Khatun, Emma Coomans, Matthew J. Betts, Federica Capraro, Elisabeth H. Thijssen, Konstantin Senkevich, Tehmina Bharucha, Mehrsa Jafarpour, Peter N. E. Young, William Jagust, Stephen F. Carter, Tammaryn Lashley, Lea T. Grinberg, Joana B. Pereira, Niklas Mattsson-Carlgren…

Young blood plasma reduces Alzheimer’s disease-like brain pathologies and ameliorates cognitive impairment in 3×Tg-AD mice

Recent studies indicated that circulatory factors in blood plasma from young animals can reactivate neurogenesis, restore synaptic plasticity, and improve cognitive function in aged animals. Here, we investiga...

Authors: Ying Zhao, Ran Qian, Jin Zhang, Fei Liu, Khalid Iqbal, Chun-Ling Dai and Cheng-Xin Gong

Immediate and long-term consequences of COVID-19 infections for the development of neurological disease

Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. While these symptoms arise acutely during the course of infection, les...

Authors: Michael T. Heneka, Douglas Golenbock, Eicke Latz, Dave Morgan and Robert Brown

Reproducibility of EEG functional connectivity in Alzheimer’s disease

Although numerous electroencephalogram (EEG) studies have described differences in functional connectivity in Alzheimer’s disease (AD) compared to healthy subjects, there is no general consensus on the methodo...

Authors: Casper T. Briels, Deborah N. Schoonhoven, Cornelis J. Stam, Hanneke de Waal, Philip Scheltens and Alida A. Gouw

A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future

Authors: Douglas Galasko and Philip Scheltens

The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease

There is growing interest in identifying sensitive composite cognitive tests to serve as primary endpoints in preclinical Alzheimer’s disease (AD) treatment trials. We reported previously a composite cognitive...

Authors: Jessica B. Langbaum, Noel N. Ellison, Angelika Caputo, Ronald G. Thomas, Carolyn Langlois, Marie-Emmanuelle Riviere, Ana Graf, Cristina Lopez Lopez, Eric M. Reiman, Pierre N. Tariot and Suzanne B. Hendrix

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alzheimer’s disease (AD). The exact pathophysiology leading to dementia is still uncertain, but the apolipoprote...

Authors: Elles Konijnenberg, Betty M. Tijms, Johan Gobom, Valerija Dobricic, Isabelle Bos, Stephanie Vos, Magda Tsolaki, Frans Verhey, Julius Popp, Pablo Martinez-Lage, Rik Vandenberghe, Alberto Lleó, Lutz Frölich, Simon Lovestone, Johannes Streffer, Lars Bertram…

Testing whether the progression of Alzheimer’s disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data

Our objectives were to develop a disease progression model for cognitive decline in Alzheimer’s disease (AD) and to determine whether disease progression of AD is related to the year of publication, add-on tri...

Authors: Ningyuan Zhang, Xijun Zheng, Hongxia Liu, Qingshan Zheng and Lujin Li

Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission

Alzheimer’s disease (AD) is the most common form of age-related neurodegenerative diseases. Cerebral deposition of Aβ peptides, especially Aβ42, is considered the major neuropathological hallmark of AD and the...

Authors: Tugce Munise Satir, Lotta Agholme, Anna Karlsson, Mattias Karlsson, Paul Karila, Sebastian Illes, Petra Bergström and Henrik Zetterberg

Physical exercise during exposure to 40-Hz light flicker improves cognitive functions in the 3xTg mouse model of Alzheimer’s disease

Exercise promotes brain health and improves cognitive functioning in the elderly, while 40-Hz light flickering through the visual cortex reduces amyloid beta (Aβ) by stabilizing gamma oscillation. We examined ...

Authors: Sang-Seo Park, Hye-Sang Park, Chang-Ju Kim, Hyun-Sik Kang, Dong-Hyun Kim, Seung-Soo Baek and Tae-Woon Kim

γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not

γ-Secretase is a multiprotein protease that cleaves amyloid protein precursor (APP) and other type I transmembrane proteins. It has two catalytic subunits, presenilins 1 and 2 (PS1 and 2). In our previous repo...

Authors: Christian B. Lessard, Edgardo Rodriguez, Thomas B. Ladd, Lisa M. Minter, Barbara A. Osborne, Lucio Miele, Todd E. Golde and Yong Ran

Is it time to use real-world data from primary care in Alzheimer’s disease?

The analysis of real-world data in clinical research is rising, but its use to study dementia subtypes has been hardly addressed. We hypothesized that real-world data might be a powerful tool to update AD epid...

Authors: Anna Ponjoan, Josep Garre-Olmo, Jordi Blanch, Ester Fages, Lia Alves-Cabratosa, Ruth Martí-Lluch, Marc Comas-Cufí, Dídac Parramon, María Garcia-Gil and Rafel Ramos

Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer’s disease and controls

Peripheral blood microRNAs (miRNA) have been identified as potential biomarkers for Alzheimer’s disease (AD). Study results have generally been inconsistent and limited by sample heterogeneity. The aim of this...

Authors: Helen Zong Ying Wu, Anbupalam Thalamuthu, Lesley Cheng, Christopher Fowler, Colin L. Masters, Perminder Sachdev and Karen A. Mather

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Aβ), was developed for oral treatment for Alzheimer’s disease (AD).

Authors: Gerald Novak, Johannes Rolf Streffer, Maarten Timmers, David Henley, H. Robert Brashear, Jennifer Bogert, Alberto Russu, Luc Janssens, Ina Tesseur, Luc Tritsmans, Luc Van Nueten and Sebastiaan Engelborghs

The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer’s disease

Lack of awareness of cognitive decline (ACD) has been described at the preclinical and prodromal stages of Alzheimer’s disease (AD). In this study, we introduced a meta-memory ratio (MMR) and explored how it i...

Authors: Geoffroy Gagliardi, Marion Houot, Federica Cacciamani, Marie-Odile Habert, Bruno Dubois and Stéphane Epelbaum

Relevance of biomarkers across different neurodegenerative diseases

The panel of fluid- and imaging-based biomarkers available for neurodegenerative disease research is growing and has the potential to close important gaps in research and the clinic. With this growth and incre...

Authors: Alexander J. Ehrenberg, Ayesha Khatun, Emma Coomans, Matthew J. Betts, Federica Capraro, Elisabeth H. Thijssen, Konstantin Senkevich, Tehmina Bharucha, Mehrsa Jafarpour, Peter N. E. Young, William Jagust, Stephen F. Carter, Tammaryn Lashley, Lea T. Grinberg, Joana B. Pereira, Niklas Mattsson-Carlgren…

Longitudinal trajectories of Alzheimer’s ATN biomarkers in elderly persons without dementia

Models of Alzheimer’s disease (AD) pathophysiology posit that amyloidosis [A] precedes and accelerates tau pathology [T] that leads to neurodegeneration [N]. Besides this A-T-N sequence, other biomarker sequen...

Authors: Meng-Shan Tan, Xi Ji, Jie-Qiong Li, Wei Xu, Hui-Fu Wang, Chen-Chen Tan, Qiang Dong, Chuan-Tao Zuo, Lan Tan, John Suckling and Jin-Tai Yu

Alzheimer’s disease progression characterized by alterations in the molecular profiles and biogenesis of brain extracellular vesicles

The contributions of brain intercellular communication mechanisms, specifically extracellular vesicles (EV), to the progression of Alzheimer’s disease (AD) remain poorly understood.

Authors: Xavier Gallart-Palau, Xue Guo, Aida Serra and Siu Kwan Sze

Correction to: Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer’s disease course

An amendment to this paper has been published and can be accessed via the original article.

Authors: Claudio Liguori, Fabio Placidi, Francesca Izzi, Matteo Spanetta, Nicola Biagio Mercuri and Alessandra Di Pucchio

Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea

Subjective cognitive decline (SCD) is a potential risk factor for dementia. We aimed to investigate the association between SCD and subsequent dementia in a nationwide population-based cohort in South Korea.

Authors: Yeong Chan Lee, Jae Myeong Kang, Hyewon Lee, Kiwon Kim, Soyeon Kim, Tae Yang Yu, Eun-Mi Lee, Clara Tammy Kim, Doh Kwan Kim, Matthew Lewis, Hong-Hee Won, Frank Jessen and Woojae Myung

The cholinergic system in subtypes of Alzheimer’s disease: an in vivo longitudinal MRI study

The heterogeneity within Alzheimer’s disease (AD) seriously challenges the development of disease-modifying treatments. We investigated volume of the basal forebrain, hippocampus, and precuneus in atrophy subt...

Authors: Alejandra Machado, Daniel Ferreira, Michel J. Grothe, Helga Eyjolfsdottir, Per M. Almqvist, Lena Cavallin, Göran Lind, Bengt Linderoth, Åke Seiger, Stefan Teipel, Lars U. Wahlberg, Lars-Olof Wahlund, Eric Westman and Maria Eriksdotter

The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer’s disease

Early-onset Alzheimer’s disease (EOAD) is characterized by young age of onset (< 65 years), severe neurodegeneration, and rapid disease progression, thus differing significantly from typical late-onset Alzheim...

Authors: Giacomo Tondo, Leonardo Iaccarino, Silvia Paola Caminiti, Luca Presotto, Roberto Santangelo, Sandro Iannaccone, Giuseppe Magnani and Daniela Perani

Imaging biomarkers in neurodegeneration: current and future practices

There is an increasing role for biological markers (biomarkers) in the understanding and diagnosis of neurodegenerative disorders. The application of imaging biomarkers specifically for the in vivo investigati...

Authors: Peter N. E. Young, Mar Estarellas, Emma Coomans, Meera Srikrishna, Helen Beaumont, Anne Maass, Ashwin V. Venkataraman, Rikki Lissaman, Daniel Jiménez, Matthew J. Betts, Eimear McGlinchey, David Berron, Antoinette O’Connor, Nick C. Fox, Joana B. Pereira, William Jagust…

The relationship between physical activity, apolipoprotein E ε4 carriage, and brain health

Neuronal hyperexcitability and hypersynchrony have been described as key features of neurophysiological dysfunctions in the Alzheimer’s disease (AD) continuum. Conversely, physical activity (PA) has been assoc...

Authors: Jaisalmer de Frutos-Lucas, Pablo Cuesta, David López-Sanz, África Peral-Suárez, Esther Cuadrado-Soto, Federico Ramírez-Toraño, Belinda M. Brown, Juan M. Serrano, Simon M. Laws, Inmaculada C. Rodríguez-Rojo, Juan Verdejo-Román, Ricardo Bruña, Maria L. Delgado-Losada, Ana Barabash, Ana M. López-Sobaler, Ramón López-Higes…

Reduction of NgR in perforant path decreases amyloid-β peptide production and ameliorates synaptic and cognitive deficits in APP/PS1 mice

Amyloid beta (Aβ) which is recognized as a main feature of Alzheimer’s disease (AD) has been proposed to “spread” through anatomically and functionally connected brain regions. The entorhinal cortex and perfor...

Authors: Rong Jiang, Xue-Fei Wu, Bin Wang, Rong-Xiao Guan, Lang-Man Lv, Ai-Ping Li, Lei Lei, Ye Ma, Na Li, Qi-Fa Li, Quan-Hong Ma, Jie Zhao and Shao Li

EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer’s disease

Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), is characterised by marked deficits within the cholinergic system which are more severe than in ...

Authors: Julia Schumacher, Alan J. Thomas, Luis R. Peraza, Michael Firbank, Ruth Cromarty, Calum A. Hamilton, Paul C. Donaghy, John T. O’Brien and John-Paul Taylor

A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse

Chronic neuroinflammation, aggressive amyloid beta (Aβ) deposition, neuronal cell loss, and cognitive impairment are pathological presentations of Alzheimer’s disease (AD). Therefore, resolution of neuroinflam...

Authors: Min Sung Gee, Seung Hwan Son, Seung Ho Jeon, Jimin Do, Namkwon Kim, Yeon-Joo Ju, Soo Jin Lee, Eun Kyoung Chung, Kyung-Soo Inn, Nam-Jung Kim and Jong Kil Lee

Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies

Dementia with Lewy bodies (DLB) is more prevalent in men than in women. In addition, post-mortem studies found sex differences in underlying pathology. It remains unclear whether these differences are also pre...

Authors: M. van de Beek, R. Babapour Mofrad, I. van Steenoven, H. Vanderstichele, P. Scheltens, C. E. Teunissen, A. W. Lemstra and W. M. van der Flier

An analysis of genetically regulated gene expression across multiple tissues implicates novel gene candidates in Alzheimer’s disease

Genome-wide association studies (GWAS) have successfully identified multiple independent genetic loci that harbour variants associated with Alzheimer’s disease, but the exact causal genes and biological pathwa...

Authors: Zachary F. Gerring, Michelle K. Lupton, Daniel Edey, Eric R. Gamazon and Eske M. Derks

Are ketogenic diets promising for Alzheimer’s disease? A translational review

Brain amyloid deposition and neurofibrillary tangles in Alzheimer’s disease (AD) are associated with complex neuroinflammatory reactions such as microglial activation and cytokine production. Glucose metabolis...

Authors: Matthieu Lilamand, Baptiste Porte, Emmanuel Cognat, Jacques Hugon, François Mouton-Liger and Claire Paquet

Improving the resistance and resilience framework for aging and dementia studies

The "resistance vs resilience" to Alzheimer’s disease (AD) framework (coping vs avoiding) has gained interest in the field in the last year. In this viewpoint, our effort is (i) to provide clarity to the usage...

Authors: Eider M. Arenaza-Urquijo and Prashanthi Vemuri

Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes

Both Alzheimer’s disease (AD) and type 2 diabetes (T2D) share common pathological features including inflammation, insulin signaling alterations, or vascular damage. AD has no successful treatment, and the clo...

Authors: Carmen Hierro-Bujalance, Carmen Infante-Garcia, Angel del Marco, Marta Herrera, Maria Jose Carranza-Naval, Javier Suarez, Pilar Alves-Martinez, Simon Lubian-Lopez and Monica Garcia-Alloza

Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal Cognitive Assessment

The Montreal Cognitive Assessment (MoCA) has good sensitivity for mild cognitive impairment, but specificity is low when the original cut-off (25/26) is used. We aim to revise the cut-off on the German MoCA fo...

Authors: Alessandra E. Thomann, Manfred Berres, Nicolai Goettel, Luzius A. Steiner and Andreas U. Monsch

Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study

Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk.

Authors: Danielle Newby, Daniel Prieto-Alhambra, Talita Duarte-Salles, David Ansell, Lars Pedersen, Johan van der Lei, Mees Mosseveld, Peter Rijnbeek, Glen James, Myriam Alexander, Peter Egger, Jana Podhorna, Robert Stewart, Gayan Perera, Paul Avillach, Solène Grosdidier…

Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative

Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Multiple studies show that patients with Alzheimer’s disease (AD...

Authors: Marta Marquié, Sergi Valero, Miguel Castilla-Marti, Joan Martínez, Octavio Rodríguez-Gómez, Ángela Sanabria, Juan Pablo Tartari, Gemma C. Monté-Rubio, Oscar Sotolongo-Grau, Montserrat Alegret, Alba Pérez-Cordón, Natalia Roberto, Itziar de Rojas, Sonia Moreno-Grau, Laura Montrreal, Isabel Hernández…

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous researc...

Authors: James D. Doecke, Larry Ward, Samantha C. Burnham, Victor L. Villemagne, Qiao-Xin Li, Steven Collins, Christopher J. Fowler, Ekaterina Manuilova, Monika Widmann, Stephanie R. Rainey-Smith, Ralph N. Martins and Colin L. Masters

Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer’s and non-Alzheimer’s dementia

Neuropsychiatric symptoms (NPS) have been reported to be useful in predicting incident dementia among cognitively normal older persons. However, the literature has not been conclusive on the differential utili...

Authors: Tau Ming Liew

In vivo staging of frontotemporal lobar degeneration TDP-43 type C pathology

TDP-43 type C is one of the pathological forms of frontotemporal lobar degeneration (FTLD) and mainly associated clinically with the semantic variant of primary progressive aphasia (svPPA). We aimed to define ...

Authors: Martina Bocchetta, Maria del Mar Iglesias Espinosa, Tammaryn Lashley, Jason D. Warren and Jonathan D. Rohrer

Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer’s disease after traumatic brain injury

Pathological analysis of brain tissue from animals and humans with a history of traumatic brain injury (TBI) suggests that TBI could be one of the risk factors facilitating onset of dementia with possible Alzh...

Authors: Mingfei Li, Joel Reisman, Benjamin Morris-Eppolito, Shirley X. Qian, Lewis E. Kazis, Benjamin Wolozin, Lee E. Goldstein and Weiming Xia

Correction to: Nrf2 activation through the PI3K/GSK-3 axisprotects neuronal cells from Aβ-mediatedoxidative and metabolic damage

After the publication of this article [1], we became aware that there were errors in Figs. 4 and 31.

Authors: Krystal Sotolongo, Jorge Ghiso and Agueda Rostagno

Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer’s disease after a 27-month delay interval

Abnormal beta-amyloid (Aβ) is associated with deleterious changes in central cholinergic tone in the very early stages of Alzheimer’s disease (AD), which may be unmasked by a cholinergic antagonist (J Prev Alz...

Authors: Jessica Alber, Paul Maruff, Cláudia Y. Santos, Brian R. Ott, Stephen P. Salloway, Don C. Yoo, Richard B. Noto, Louisa I. Thompson, Danielle Goldfarb, Edmund Arthur, Alex Song and Peter J. Snyder

The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment

As research in treatments for neurocognitive diseases progresses, there is an increasing need to identify cognitive decline in the earliest stages of disease for initiation of treatment in addition to determin...

Authors: Emma Borland, Erik Stomrud, Danielle van Westen, Oskar Hansson and Sebastian Palmqvist

Characterization of the chromatin accessibility in an Alzheimer’s disease (AD) mouse model

The pathological hallmarks of Alzheimer’s disease (AD) involve alterations in the expression of numerous genes associated with transcriptional levels, which are determined by chromatin accessibility. Here, the...

Authors: Yaqi Wang, Xiaomin Zhang, Qiao Song, Yuli Hou, Jing Liu, Yu Sun and Peichang Wang

Effects of low- and high-intensity physical exercise on physical and cognitive function in older persons with dementia: a randomized controlled trial

Potential moderators such as exercise intensity or apolipoprotein-E4 (ApoE4) carriership may determine the magnitude of exercise effects on physical and cognitive functions in patients with dementia (PwD). We ...

Authors: L. M. J. Sanders, T. Hortobágyi, E. G. A. Karssemeijer, E. A. Van der Zee, E. J. A. Scherder and M. J. G. van Heuvelen

Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase

Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD), but diagnosis of AD in DS is challenging due to the intellectual disability which accompanies DS. When disease-modifying agents ...

Authors: David Mengel, Wen Liu, Robert J. Glynn, Dennis J. Selkoe, Andre Strydom, Florence Lai, H. Diana Rosas, Amy Torres, Vasiliki Patsiogiannis, Brian Skotko and Dominic M. Walsh

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

Cerebrospinal fluid biomarker profiles characterized by decreased amyloid-beta peptide levels and increased total and phosphorylated tau levels at threonine 181 (pT181) are currently used to discriminate betwe...

Authors: Nicolas R. Barthélemy, Randall J. Bateman, Christophe Hirtz, Philippe Marin, François Becher, Chihiro Sato, Audrey Gabelle and Sylvain Lehmann